A Phase II Pilot Trial to Evaluate CoBaT-Y017 Safety and Efficacy against Uncomplicated Falciparum Malaria versus Artemether-Lumefantrine in Benin Subjects

Table 3

Variation of mean of AST and ALT values of patients at different follow-up days in the study arms.

Parameters	Treatment arms	D1 (baseline)	D4	D7	D14	D21	D28
AST	CoBaT-Y017	25.66 ± 18.29	28.41 ± 15.46	28.20 ± 17.26	22.96 ± 14.89	19.07 ± 5.40	20.81 ± 7.95
	AL	19.06 ± 11.89	19.09 ± 6.60	15.85 ± 5.78	22.26 ± 9.50	19.72 ± 9.53	15.88 ± 4.17
ALT	CoBaT-Y017	26.94 ± 18.89	29.91 ± 17.22	34.25 ± 23.16	22.79 ± 9.30	24.64 ± 18.98	21.21 ± 10.61
	AL	21.12 ± 13.83	19.85 ± 10.06	19.15 ± 6.72	22.69 ± 14.63	21.06 ± 12.85	19.49 ± 10.17

Values were expressed as mean ± SD.